BBLG
- Bone Biologics Corporation
()
Overview
Company Summary
Bone Biologics Corporation (BBLG) is a company that focuses on developing innovative regenerative medicine solutions for the treatment of orthopedic conditions and injuries. They specialize in developing and commercializing products that harness the body's natural healing process to stimulate bone growth and repair.
The primary focus of BBLG is the development of a technology called recombinant human protein (rhPTH), which is a synthetic version of a naturally occurring protein in the body called parathyroid hormone. This protein plays a crucial role in bone formation and remodeling by stimulating the production of new bone cells, enhancing bone density, and promoting bone healing.
BBLG's flagship product is called NELL-1, a genetically engineered rhPTH-based therapy. NELL-1 has shown promising results in preclinical and clinical trials for various orthopedic applications, including spinal fusion, bone fractures, non-union fractures (fractures that fail to heal properly), and osteoporosis (a condition characterized by weak and brittle bones).
The company's goal is to provide surgeons with safe and effective regenerative medicine solutions that can significantly improve patient outcomes, reduce recovery time, and enhance the overall quality of life for individuals suffering from bone-related conditions. By leveraging their expertise in protein engineering and bone biology, BBLG aims to revolutionize the field of orthopedic medicine and become a leader in regenerative therapies.
In summary, Bone Biologics Corporation focuses on developing and commercializing regenerative medicine solutions, primarily utilizing recombinant human protein technology, to enhance bone growth, repair fractures, and improve overall orthopedic outcomes.